Kirsten Craven

Inside the box: Complementary fragmentation with LC-MS for Metabolite Identification

Feb 7, 2025 | Blogs, Pharma, ZenoTOF 7600 system | 0 comments

Read Time: 2 Minutes

Introduction

Liquid chromatography-mass spectrometry is commonly used for Met ID but confident soft spot identification is not always possible. Imagine the advantage of unambiguous metabolite identification using liquid chromatography-mass spectrometry (LC-MS) reducing the need for additional safety testing during drug discovery. Quickly and easily generate the information you need using routine assays that are robust and efficient, enabling confident decision-making while also saving time and money. Learn more >

Streamline Met ID with additional fragmentation information

Metabolite identification is a key task during drug discovery to establish safety and efficacy of a drug candidate. LC-MS assays for metabolite identification typically use collision-induced dissociation (CID) to fragment ions for structural elucidation, and soft-spot identification. With challenging metabolites, CID doesn’t produce sufficient fragment ions or help with labile modifications and a clear identification cannot be made. This can lead to the need for additional testing to meet regulatory requirements.

What is electron-activated dissociate (EAD)?

EAD is a fragmentation method available on the ZenoTOF 7600 system that causes ions in an LC-MS/MS experiment to fragment in locations that are different from where they fragment with CID, providing additional information to scientists. For metabolite identification, this could mean confident identification of the metabolite and localization of the site of metabolism, removing the need for additional safety testing.

Curious to know more? Watch our on-demand Met ID webinars, here? LINK WILL COME FROM HERE https://sciex.kapost.com/posts/pharma-webinar-content-hub-lp-and-typ

Why traditional MS/MS falls short for ADCs and how electron-activated dissociation (EAD) changes the equation

Antibody-drug conjugates (ADCs) are among the most promising—and analytically demanding—modalities in biopharma today. By combining large, heterogeneous antibodies with chemically labile payloads and linkers, ADCs introduce a level of structural complexity that challenges conventional analytical workflows. It also poses the challenge that the very features you need to measure are often the easiest to lose during analysis.

Six benefits of remote support every laboratory should know

Imagine having a tech expert at your fingertips to solve computer issues or a fitness trainer guiding you through workouts from the comfort of your home. In today’s fast-paced world, the ability to provide and receive service and support remotely is no longer a luxury but a necessity. Whether it’s troubleshooting a software issue, repairing a device, offering customer assistance, or enjoying the convenience of telehealth as a private individual, remote capabilities have revolutionized how businesses operate and how individuals get help

The costly consequences of unplanned downtime

Unplanned downtime is a formidable adversary that businesses across various industries strive to minimize. Defined as the unexpected interruption of regular operations, unplanned downtime can wreak havoc on productivity, profitability and customer satisfaction. In this article, we delve into the causes of unplanned downtime, its far-reaching consequences and strategies to mitigate its impact.

Posted by

Kirsten Craven

Kirsten Craven is the Senior Global Marketing Manager for Pharma global strategic marketing at SCIEX. In this role, she manages strategic marketing for the pharmaceutical industry. Kirsten spent the first part of her career working in laboratories across multiple industries before moving into product management, and most recently pharma marketing.

0 Comments